Forbes June 29, 2022
Alex Zhavoronkov, PhD

While the industry is not yet moving at the pace I expected many years ago, as people choose to focus on issues that they believe are more urgent than longevity, there is definitely more activity in longevity biotechnology than 20 years ago.

Usually, as we have observed with the Internet, semiconductors, and mobile phones, as the industry grows, it tends to sprout the information and analytical portals, discussion groups, and other community resources.

In longevity biotechnology, several such portals emerged in recent years. Non-profit resources such as Lifespan.io catering to the general public and focusing on advocacy, collections of tools such as senescense.info run by Dr. Joao Pedro de Magalhaes, community blogs such as FightAging.org, etc. But one standout, for-profit...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma / Biotech, Provider
Will Synthetic, AI-Based Digital Humans Change Pharma and Life Sciences? Q&A with Abid Rahman, SVP Innovation, EVERSANA
Cerevel Parkinson’s data adds lustre to AbbVie acquisition
Pharma Pulse 4/19/24: The Health and Healthcare of Gen-Z, Long-Acting Drugs May Revolutionize HIV Prevention/Treatment & more
Recursion, Canaan, Metsera and more—Chutes & Ladders
Unlocking Targeted Cancer Care: Biomarkers as the Key to Personalized Treatments

Share This Article